Long-term effectiveness and safety of nutraceutical based approch to reduce cholesterolemia in statin intollerant subjects with and without metabolic syndrome.

Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice.

July 2015

none2To verify the efficacy of a patented proprietary combination of nutraceuticals containing natur...

REDUCTION OF CHOLESTEROL WITH NUTRACEUTICAL: RESULTS OF A DOUBLE BLIND STUDY

Longo, F.
Panno, M.
Giammanco, A.
Altieri, G.
Di Pietra, A.
Portera, D.
Averna, M.
Barbagallo, C.

January 2013

A large body of evidence has demonstrated that LDL-C reduction by statins decrease cardiovascular ri...

Nutraceuticals and dyslipidaemia: beyond the common therapeutics

Scicchitano, Pietro
Cameli, Matteo
Maiello, Maria
Modesti, Pietro Amedeo
Muiesan, Maria Lorenza
Novo, Salvatore
Palmiero, Pasquale
Saba, Pier Sergio
Pedrinelli, Roberto
Ciccone, Marco Matteo

January 2014

Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins represent...

Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome.

CICERO, ARRIGO FRANCESCO GIUSEPPE
BOVE, MARILISA
IMOLA, FABRIZIO
BORGHI, CLAUDIO
G. Derosa
A. V. Gaddi

January 2009

The aim of our study was to test the long-term effectiveness and tolerability of a nutraceutical bas...

A nutraceutical based approach to reduce cholesterolemia in patients previously intolerant to more than a statin: a pilot study.

CICERO, ARRIGO FRANCESCO GIUSEPPE
BOVE, MARILISA
GRANDI, ELISA
BORGHI, CLAUDIO
GADDI, ANTONIO VITTORINO
Derosa G
Uliassi E

January 2008

This study was aimed at evaluating the tolerability of a nutraceutical combination with anticholeste...

Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients.

CICERO, ARRIGO FRANCESCO GIUSEPPE
DE SANDO, VALERIA
GRANDI, ELISA
BORGHI, CLAUDIO
Benedetto D
Cevenini M

January 2012

The short-term lipid-lowering activity of some nutraceuticals is well-known, however there is a lack...

The Role of Nutraceuticals in Statin Intolerant Patients.

Banach, Maciej
Patti, Angelo Maria
Giglio, Rosaria Vincenza
Cicero, Arrigo F G
Atanasov, Atanas G
Bajraktari, Gani
Bruckert, Eric
Descamps, Olivier
Djuric, Dragan M
Ezhov, Marat
Fras, Zlatko
von Haehling, Stephan
Katsiki, Niki
Langlois, Michel
Latkovskis, Gustavs
Mancini, G B John
Mikhailidis, Dimitri P
Mitchenko, Olena
Moriarty, Patrick M
Muntner, Paul
Nikolic, Dragana
Panagiotakos, Demosthenes B
Paragh, Gyorgy
Paulweber, Bernhard
Pella, Daniel
Pitsavos, Christos
Reiner, Željko
Rosano, Giuseppe M C
Rosenson, Robert S
Rysz, Jacek
Sahebkar, Amirhossein
Serban, Maria-Corina
Vinereanu, Dragos
Vrablík, Michal
Watts, Gerald F
Wong, Nathan D
Rizzo, Manfredi
International Lipid Expert Panel (ILEP)

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid lowering properties: a randomized clinical trial.

Cicero AFG
Bove M
Gerocarni B
Giovannini M
Borghi C.

January 2011

This is a double-blind, placebo-controlled clinical trial on a combined nutraceutical non containing...

The Role of Nutraceuticals in Statin Intolerant Patients.

February 2019

none37siStatins are the most common drugs administered for patients with cardiovascular disease. How...

The role of nutraceuticals in statin intolerant patients

Banach, Maciej
Patti, Angelo Maria
Giglio, Rosaria Vincenza
Cicero, Arrigo F.G.
Atanasov, Atanas G.
Bajraktari, Gani
Bruckert, Eric
Descamps, Olivier
Djuric, Dragan M.
Ezhov, Marat
Fras, Zlatko
von Haehling, Stephan
Katsiki, Niki
Langlois, Michel
Latkovskis, Gustavs
Mancini, G.B. John
Mikhailidis, Dimitri P.
Mitchenko, Olena
Moriarty, Patrick M.
Muntner, Paul
Nikolic, Dragana
Panagiotakos, Demosthenes B.
Paragh, Gyorgy
Paulweber, Bernhard
Pella, Daniel
Pitsavos, Christos
Reiner, Željko
Rosano, Giuseppe M.C.
Rosenson, Robert S.
Rysz, Jacek
Sahebkar, Amirhossein
Serban, Maria-Corina
Vinereanu, Dragos
Vrablík, Michal
Watts, Gerald F.
Wong, Nathan D.
Rizzo, Manfredi

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Nutraceuticals and cholesterol-lowering action

Martina Rosticci
Angelo Parini
Arrigo F G Cicero

March 2015

Abstract Nutraceuticals play an important role in cardiovascular prevention in patients with dyslipi...

A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence

January 2018

none7siCompelling evidence supports the effectiveness of the reduction of total and LDL cholesterol ...

Natural approaches in metabolic syndrome management.

February 2019

none13siMetabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that r...

The Role of Nutraceuticals in Statin Intolerant Patients

Banach M.
Patti A. M.
Giglio R. V.
Cicero A. F. G.
Atanasov A. G.
Bajraktari G.
Bruckert E.
Descamps O.
Djuric D. M.
Ezhov M.
Fras Z.
von Haehling S.
Katsiki N.
Langlois M.
Latkovskis G.
Mancini G. B. J.
Mikhailidis D. P.
Mitchenko O.
Moriarty P. M.
Muntner P.
Nikolic D.
Panagiotakos D. B.
Paragh G.
Paulweber B.
Pella D.
Pitsavos C.
Reiner Z.
Rosano G. M. C.
Rosenson R. S.
Rysz J.
Sahebkar A.
Serban M. -C.
Vinereanu D.
Vrablik M.
Watts G. F.
Wong N. D.
Rizzo Manfredi

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Lipid-lowering nutraceuticals update on scientific evidence

February 2021

none10noCardiovascular diseases (CVDs) are the main cause of mortality worldwide. Risk factors of CV...

Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice.

July 2015

none2To verify the efficacy of a patented proprietary combination of nutraceuticals containing natur...

REDUCTION OF CHOLESTEROL WITH NUTRACEUTICAL: RESULTS OF A DOUBLE BLIND STUDY

Longo, F.
Panno, M.
Giammanco, A.
Altieri, G.
Di Pietra, A.
Portera, D.
Averna, M.
Barbagallo, C.

January 2013

A large body of evidence has demonstrated that LDL-C reduction by statins decrease cardiovascular ri...

Nutraceuticals and dyslipidaemia: beyond the common therapeutics

Scicchitano, Pietro
Cameli, Matteo
Maiello, Maria
Modesti, Pietro Amedeo
Muiesan, Maria Lorenza
Novo, Salvatore
Palmiero, Pasquale
Saba, Pier Sergio
Pedrinelli, Roberto
Ciccone, Marco Matteo

January 2014

Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins represent...

Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome.

CICERO, ARRIGO FRANCESCO GIUSEPPE
BOVE, MARILISA
IMOLA, FABRIZIO
BORGHI, CLAUDIO
G. Derosa
A. V. Gaddi

January 2009

The aim of our study was to test the long-term effectiveness and tolerability of a nutraceutical bas...

A nutraceutical based approach to reduce cholesterolemia in patients previously intolerant to more than a statin: a pilot study.

CICERO, ARRIGO FRANCESCO GIUSEPPE
BOVE, MARILISA
GRANDI, ELISA
BORGHI, CLAUDIO
GADDI, ANTONIO VITTORINO
Derosa G
Uliassi E

January 2008

This study was aimed at evaluating the tolerability of a nutraceutical combination with anticholeste...

Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients.

CICERO, ARRIGO FRANCESCO GIUSEPPE
DE SANDO, VALERIA
GRANDI, ELISA
BORGHI, CLAUDIO
Benedetto D
Cevenini M

January 2012

The short-term lipid-lowering activity of some nutraceuticals is well-known, however there is a lack...

The Role of Nutraceuticals in Statin Intolerant Patients.

Banach, Maciej
Patti, Angelo Maria
Giglio, Rosaria Vincenza
Cicero, Arrigo F G
Atanasov, Atanas G
Bajraktari, Gani
Bruckert, Eric
Descamps, Olivier
Djuric, Dragan M
Ezhov, Marat
Fras, Zlatko
von Haehling, Stephan
Katsiki, Niki
Langlois, Michel
Latkovskis, Gustavs
Mancini, G B John
Mikhailidis, Dimitri P
Mitchenko, Olena
Moriarty, Patrick M
Muntner, Paul
Nikolic, Dragana
Panagiotakos, Demosthenes B
Paragh, Gyorgy
Paulweber, Bernhard
Pella, Daniel
Pitsavos, Christos
Reiner, Željko
Rosano, Giuseppe M C
Rosenson, Robert S
Rysz, Jacek
Sahebkar, Amirhossein
Serban, Maria-Corina
Vinereanu, Dragos
Vrablík, Michal
Watts, Gerald F
Wong, Nathan D
Rizzo, Manfredi
International Lipid Expert Panel (ILEP)

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid lowering properties: a randomized clinical trial.

Cicero AFG
Bove M
Gerocarni B
Giovannini M
Borghi C.

January 2011

This is a double-blind, placebo-controlled clinical trial on a combined nutraceutical non containing...

The Role of Nutraceuticals in Statin Intolerant Patients.

February 2019

none37siStatins are the most common drugs administered for patients with cardiovascular disease. How...

The role of nutraceuticals in statin intolerant patients

Banach, Maciej
Patti, Angelo Maria
Giglio, Rosaria Vincenza
Cicero, Arrigo F.G.
Atanasov, Atanas G.
Bajraktari, Gani
Bruckert, Eric
Descamps, Olivier
Djuric, Dragan M.
Ezhov, Marat
Fras, Zlatko
von Haehling, Stephan
Katsiki, Niki
Langlois, Michel
Latkovskis, Gustavs
Mancini, G.B. John
Mikhailidis, Dimitri P.
Mitchenko, Olena
Moriarty, Patrick M.
Muntner, Paul
Nikolic, Dragana
Panagiotakos, Demosthenes B.
Paragh, Gyorgy
Paulweber, Bernhard
Pella, Daniel
Pitsavos, Christos
Reiner, Željko
Rosano, Giuseppe M.C.
Rosenson, Robert S.
Rysz, Jacek
Sahebkar, Amirhossein
Serban, Maria-Corina
Vinereanu, Dragos
Vrablík, Michal
Watts, Gerald F.
Wong, Nathan D.
Rizzo, Manfredi

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Nutraceuticals and cholesterol-lowering action

Martina Rosticci
Angelo Parini
Arrigo F G Cicero

March 2015

Abstract Nutraceuticals play an important role in cardiovascular prevention in patients with dyslipi...

A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence

January 2018

none7siCompelling evidence supports the effectiveness of the reduction of total and LDL cholesterol ...

Natural approaches in metabolic syndrome management.

February 2019

none13siMetabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that r...

The Role of Nutraceuticals in Statin Intolerant Patients

Banach M.
Patti A. M.
Giglio R. V.
Cicero A. F. G.
Atanasov A. G.
Bajraktari G.
Bruckert E.
Descamps O.
Djuric D. M.
Ezhov M.
Fras Z.
von Haehling S.
Katsiki N.
Langlois M.
Latkovskis G.
Mancini G. B. J.
Mikhailidis D. P.
Mitchenko O.
Moriarty P. M.
Muntner P.
Nikolic D.
Panagiotakos D. B.
Paragh G.
Paulweber B.
Pella D.
Pitsavos C.
Reiner Z.
Rosano G. M. C.
Rosenson R. S.
Rysz J.
Sahebkar A.
Serban M. -C.
Vinereanu D.
Vrablik M.
Watts G. F.
Wong N. D.
Rizzo Manfredi

January 2018

Statins are the most common drugs administered for patients with cardiovascular disease. However, du...

Lipid-lowering nutraceuticals update on scientific evidence

February 2021

none10noCardiovascular diseases (CVDs) are the main cause of mortality worldwide. Risk factors of CV...

Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice.

July 2015

none2To verify the efficacy of a patented proprietary combination of nutraceuticals containing natur...

REDUCTION OF CHOLESTEROL WITH NUTRACEUTICAL: RESULTS OF A DOUBLE BLIND STUDY

Longo, F.
Panno, M.
Giammanco, A.
Altieri, G.
Di Pietra, A.
Portera, D.
Averna, M.
Barbagallo, C.

January 2013

A large body of evidence has demonstrated that LDL-C reduction by statins decrease cardiovascular ri...

Nutraceuticals and dyslipidaemia: beyond the common therapeutics

Scicchitano, Pietro
Cameli, Matteo
Maiello, Maria
Modesti, Pietro Amedeo
Muiesan, Maria Lorenza
Novo, Salvatore
Palmiero, Pasquale
Saba, Pier Sergio
Pedrinelli, Roberto
Ciccone, Marco Matteo

January 2014

Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins represent...

Long-term effectiveness and safety of nutraceutical based approch to reduce cholesterolemia in statin intollerant subjects with and without metabolic syndrome.

Abstract

Extracted data

Long-term effectiveness and safety of nutraceutical based approch to reduce cholesterolemia in statin intollerant subjects with and without metabolic syndrome.

Abstract

Extracted data

Related items

Related items